Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00513786
Status:
COMPLETED
Last Update Posted:
2017-08-01
First Post:
2007-08-08
Brief Title:
Evaluation of CarboplatinPaclitaxelBevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Sponsor:
David OMalley
Organization:
Ohio State University Comprehensive Cancer Center
Study Overview
Official Title:
A Phase II Study of CarboplatinPaclitaxelBevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Purpose of this study is to determine the effectiveness of the drug combination carboplatin paclitaxel and bevacizumabAvastin in patients with advanced stage endometrial carcinoma
Detailed Description:
The purpose of this study is to test the effectiveness safety and tolerability of the drug combination carboplatin paclitaxel and bevacizumabAvastin in patients with advanced stage endometrial carcinoma This is a phase IIopen labelsingle center study Patients will receive carboplatin paclitaxel and bevacizumab in an outpatient center by intravenous administration The primary objectives is to study the progression free survival at 24 months after initiation of treatment and to determine the toxicity profile of the drug combinations The secondary objectives are to estimate the overall survival and tumor response for this group of patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2012-01229 | REGISTRY | Clinical Trials Reporting Program CTRP | None |